Top 3 Health Care Stocks That May Collapse This Quarter
Top 3 Health Care Stocks That May Collapse This Quarter
As of Dec. 11, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
截至2024年12月11日，医疗保健板块的三只股票可能向重视交易决策中动量作为关键标准的投资者发出真正的警告。
The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down. When compared to a stock's price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the RSI is above 70, according to Benzinga Pro.
相对强弱指数（RSI）是一种动量指标，它比较股票在价格上涨时的强度与在价格下跌时的强度。与股票的价格动态相比，它可以让交易者更好地了解股票在短期内的表现。根据Benzinga Pro的说法，当RSI超过70时，资产通常被视为超买。
Here's the latest list of major overbought players in this sector.
以下是该板块最新的主要超买股票名单。
Adaptive Biotechnologies Corp (NASDAQ:ADPT)
Adaptive Biotechnologies Corp (纳斯达克:ADPT)
- On Dec. 7, Adaptive Biotechnologies presented new data at ASH 2024 showcasing clonoSEQ MRD testing advances and its role in guiding blood cancer treatment decisions. The company's shares gained around 6% over the past month and has a 52-week high of $7.07.
- RSI Value: 75.83
- ADPT Price Action: Shares of Adaptive Biotechnologies gained 4.2% to close at $6.71 on Tuesday.
- 在2024年ASH大会上，Adaptive Biotechnologies于12月7日展示了新数据，展示了clonoSEQ MRD测试的进展及其在指导血癌治疗决策中的作用。该公司的股票在过去一个月上涨了大约6%，并且在过去52周内的最高价为$7.07。
- RSI值：75.83
- ADPT价格走势：Adaptive Biotechnologies的股票在周二上涨了4.2%，收于$6.71。
NewAmsterdam Pharma Company NV (NASDAQ:NAMS)
NewAmsterdam Pharma Company NV (纳斯达克:NAMS)
- On Dec. 10, NewAmsterdam Pharma revealed topline data from its Phase 3 BROADWAY clinical trial evaluating obicetrapib in adult patients with atherosclerotic cardiovascular disease (ASCVD) and/or heterozygous familial hypercholesterolemia (HeFH), whose LDL-C is not adequately controlled, despite being on maximally tolerated lipid-lowering therapy. The company's stock gained around 30% over the past five days and has a 52-week high of $26.36.
- RSI Value: 81.17
- NAMS Price Action: Shares of NewAmsterdam Pharma jumped 41.4% to close at $26.19 on Tuesday.
- 12月10日，NewAmsterdam Pharma公布了其第3期BROADWAY临床试验的顶线数据，该试验评估了在动脉粥样硬化性心血管疾病（ASCVD）和/或杂合子家族性高胆固醇血症（HeFH）成年患者中使用obicetrapib，尽管接受了最大耐受剂量的降脂治疗，但其LDL-C未得到充分控制。公司的股票在过去五天内上涨了约30%，其52周高点为26.36美元。
- RSI值：81.17
- NAMS价格动态：NewAmsterdam Pharma的股票在周二上涨了41.4%，收于26.19美元。
Paragon 28 Inc (NYSE:FNA)
Paragon 28 Inc (纽交所:FNA)
- On Nov. 12, Paragon 28 reported quarterly losses of 15 cents per share which met the analyst consensus estimate. The company reported quarterly sales of $62.30 million which beat the analyst consensus estimate of $60.58 million. The company's stock gained around 38% over the past month and has a 52-week high of $14.79.
- RSI Value: 77.07
- FNA Price Action: Shares of Paragon 28 gained 5% to close at $10.50 on Tuesday.
- 11月12日，Paragon 28报告每股损失15美分，符合分析师共识预期。该公司报告季度销售额为6230万美元，高于分析师共识预期的6058万美元。公司的股票在过去一个月内上涨了约38%，其52周高点为14.79美元。
- RSI值：77.07
- FNA价格动态：Paragon 28的股票在周二上涨了5%，收于10.50美元。
Read This Next:
接下来请阅读：
- Dow Falls For 4th Straight Session, Alphabet Surges On Google Quantum Chip Announcement: Fear & Greed Index Remains In 'Neutral' Zone
- 道琼斯连续第四个交易日下跌，Alphabet因谷歌量子芯片公告而飙升：恐惧与贪婪指数仍处于‘中立’区域
